Technology Overview

The Opportunity
The current vaccine market is estimated at $7 billion. Redefined by new vaccine technology, the market is expected to triple to more than $20 billion by 2015. The future vaccine market will take advantage of advances in immunology, genetics, and molecular biology to address a whole new range of cancer and infectious disease targets.

Historically, the market for vaccine products to combat infectious diseases and cancers has been small, and has lagged far behind the growth of therapeutic products to treat these diseases. Low-priced, expensive to produce, and outdated technologies currently produce vaccines for relatively few diseases.

Future vaccine technologies will provide highly cost-effective alternatives to conventional treatments, while at the same time creating a significant commercial opportunity for vaccine manufacturers.

AlphaVax is in an excellent position to lead the technological revolution of the vaccine marketplace. Our Alphavaccine Platform System has great potential for a variety of applications as an immunologically active genetic delivery system for vaccination against infectious diseases and cancer.